Candida bloodstream infections in hemodialysis recipients

Medical Mycology

Volumn 47, Issue 5, 2009, Pages 463-467

  Pyrgos, Vasilios ^a   Ratanavanich, Kathryn ^b   Donegan, Nancy ^a   Veis, Judith ^b   Walsh, Thomas J ^c   Shoham, Shmuel ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Section of Nephrology

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Candidemia; Epidemiology; Hemodialysis; Infection

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL INFECTION; HUMAN; INTRAVASCULAR CATHETER; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPENIA; NONHUMAN; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; TOTAL PARENTERAL NUTRITION; UNIVARIATE ANALYSIS;

ADULT; ANALYSIS OF VARIANCE; CANDIDIASIS; CASE-CONTROL STUDIES; CHILD; DISTRICT OF COLUMBIA; FUNGEMIA; HUMANS; LOGISTIC MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

CANDIDA; CANDIDA GLABRATA; FISTULA;

EID: 70749122825     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802369332     Document Type: Article

References (40)

1. National Institute of Health N: US Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, Maryland, 2004.
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-2353.
3. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-186.
4. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007; 50: 302-310.
5. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
6. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a populationbased active surveillance. Clin Infect Dis 1999; 29: 1164-1170.
7. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Medn 2003; 348: 1123-1133.
8. Sofair AN, Lyon GM, Huie-White S, et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis 2006; 43: 32-39.
9. Walsh TJ, Gonzalez C, Roilides E, et al. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis 1995; 20: 900-906.
10. Karabinis A, Hill C, Leclercq B, et al. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26: 429-432.
11. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-324. (Pubitemid 30213071)
12. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-381.
13. Sehgal AR, Snow RJ, Singer ME, et al. Barriers to adequate delivery of hemodialysis. Am J Kidney Dis 1998; 31: 593-601.
14. Sardenberg C, Suassuna P, Andreoli MC, et al. Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant 2006; 21: 160-165.
15. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg 1999; 134: 657-64; discussion 664-665.
16. Cano MV, Perz JF, Craig AS, et al. Candidemia in pediatric outpatients receiving home total parenteral nutrition. Med Mycol 2005; 43: 219-225.
17. Montgomerie JZ, Edwards JE Jr. Association of infection due to Candida albicans with intravenous hyperalimentation. J Infect Dis 1978; 137: 197-201.
18. Melly MA, Meng HC, Schaffner W. Microbiol growth in lipid emulsions used in parenteral nutrition. Arch Surg 1975; 110: 1479-1481.
19. Lederer T, Rippon J, Baldwin S, Pachman LM. The effect of parenteral alimentation fluid, undiluted with saline or fresh sera, on the growth of Candida albicans in vitro at 378C. Mycopathologia 1975; 55: 65-69.
20. Lawrence J, Turner M, Gilbert P. Microbial contamination and growth in total parenteral nutrition solutions. J Clin Pharm Ther 1988; 13: 151-157.
21. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235-243.
22. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998-2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
23. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998; 36: 1886-1889.
24. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-385.
25. Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33: 1676-1681.
26. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555-4560.
27. Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999; 37: 531-537.
28. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-1302.
29. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-623.
30. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128. (Pubitemid 127774267)
31. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17: 504-508.
32. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
33. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
34. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
35. Engelich G, Wright DG, Hartshorn KL. Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis 2001; 33: 2040-2048.
36. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fc gamma receptors in end-stage renal disease. N Engl J Med 1990; 322: 717-722.
37. Jorstad S, Smeby LC, Wideroe TE, Berg KJ. Transport of uremic toxins through conventional hemodialysis membranes. Clin Nephrol 1979; 12: 168-173.
38. Gibbons RA, Martinez OM, Garovoy MR. Altered monocyte function in uremia. Clin Immunol Immunopathol 1990; 56: 66-80.
39. Jorstad S, Viken KE. Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand 1977; 85: 169-177.
40. Heidenreich S, Schmidt M, Bachmann J, Harrach B. Apoptosis of monocytes cultured from long-term hemodialysis patients. Kidney Int 1996; 49: 792-799.